BioNTech Announces Plans for Taiwan Clinical Trial Hub

The security has added 41% over the last six months

Digital Content Manager
Dec 16, 2022 at 10:01 AM
facebook twitter linkedin

BioNTech SE (NASDAQ:BNTX) announced plans today for a clinical trial hub in Taiwan for its MRNA-based cancer immunotherapies. The move comes as part of the company's Asia-Pacific expansion, with the first clinical trial site to be activated to evaluate its candidate treatment against head and neck cancer. At last check, BNTX is off 0.8% at $180.54.

The security has added 42.3% in the last six months, but year-over-year it maintains a hefty 36.1% deficit. Prior to today's pullback, shares had been rallying from a dip to the $118 level, but a new ceiling currently appears to be forming around the $190 region.

Calls are all the rage in the options pits. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 50-day put/call volume ratio of 4.66 ranks higher than 99% of readings from the last 12 months, meaning long calls have been getting picked up at a much quicker-than-usual clip.

BioNTech stock sports affordable options at the moment, too. This is per its Schaeffer’s Volatility Index (SVI) of 55%, which ranks in the relatively low 12th percentile of readings from the past 12 months.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners